As exposure must include speciation dependent. In short, methylated As is a ubiquitous environmental contaminant, presents significant human health risks: Chronic exposure is associated with the development of cancer in the bladder, liver, kidney, and lungs (Chen et al. 1992). Regions with a high geogenic As background show an increased risk for elevated exposure by consumption of drinking water and diet. An additional exposure scenario in urban areas near smelting and mining activities is the ingestion of contaminated soil and dust by children who display typical hand-to-mouth behavior. Although inorganic As (iAs) may be the predominant form in contaminated soils, As speciation changes during gastrointestinal transit are not well characterized. The gut represents a complex microbial community, which may contribute to the presystemic biotransformation of inorganic As (systemic metabolism being defined as all metabolic reactions carried out by human cells). Presystemic As speciation analysis must therefore be considered an essential part of the risk evaluation process, especially with respect to toxicity, which is speciation dependent. In short, methylated trivalent species—monomethylarsonous acid (MMAIII), dimethylarsinous acid (DMAIII), and arsenous acid (iAsIII)—are two orders of magnitude more cytotoxic than is As acid (iAsV) (Naranmandura et al. 2007a). The methylated pentavalent species—monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV)—present a 10-fold lower toxicity than iAsV, whereas trimethylarsine oxide (TMAO) is essentially nontoxic (Hirano et al. 2004).

In the human body, iAs is sequentially methylelated and predominately excreted as DMAV in urine. This methylation process was originally considered a detoxification process, but the formation of reactive intermediates (MMAIII and DMAIII) has forced researchers to reconsider methylation as an activation process (Styblo et al. 2002). In addition, a recent study on human urine analysis after iAs exposure revealed new sulfur-containing methylated As metabolites, monomethylmonothioarsenic acid (MMMTA) and dimethylmonothioarsinic acid (DMMTA) (Naranmandura et al. 2007b; Raml et al. 2007), for which the mechanism of formation and toxicological profile are not yet fully characterized. Given the toxicological importance of As speciation changes, it is clear that a complete risk characterization after As exposure must include the possibility of presystemic metabolism by the microbe-rich environment of the gastrointestinal tract.

The colon harbors a vast (1014 bacterial cells) and incredibly diverse (> 1,000 species) microbial community, which has the ability to metabolize xenobiotics far more extensively than any other part of the body (Souza et al. 2008). Thus far, the presystemic bio-transformation of As was primarily studied with gut microbiota from animal models. Rowland and Davies (1981) reported the reduction of iAsV to iAsIII by rat cecal bacteria as well as limited formation of MMA and DMA. In another study with rats orally exposed to DMAV Chen et al. (1996) detected demethylated (iAsV, MMAV) and methylated (TMAO) urinary metabolites. Finally, the thiolation of methylated As oxides (DMAV, TMAO) in the cecal contents of a mouse (Kubachka et al. 2009a, 2009b) and the observed thiolation through in vivo experiments (Kuroda et al. 2004; Naranmandura et al. 2007b) have been reported.

Presystemic As metabolism in the human body has been less investigated (Hirner et al. 2004). Nevertheless, Michalke et al. (2008) reported that human gut microbes actively volatilize bismuth and other metalloids, including As, through methylation and de-aromatization pathways.

Address correspondence to T. Van de Wiele, Laboratory Microbial Ecology and Technology, Ghent University, 653 Couverture Links, B-9000 Gent, Belgium. Telephone: 32-9-264-59-76. Fax: 32-9-264-62-48. E-mail: tom.vandewiele@ugent.be

Supplemental Material is available online (doi:10.1289/ehp.0901794)
Postulated that gut methanogens play a crucial role in metalloid volatilization, thereby exerting toxic effects to the human body—not only by direct interaction with the host but also by disturbing the endogenous gut microbiota composition and metabolism. Finally, a thorough in vitro exploration with the Simulator of the Human Intestinal Microbial Ecosystem (SHIME), a dynamic human gastrointestinal simulator, revealed a high microbial metabolic potency toward metalloids (Díaz-Bone and Van de Wiele 2009). This was demonstrated by the finding of significant volatilization of As, selenium, bismuth, tellurium (Te), and antimony; the formation of highly toxic \( \text{AsH}_3 \) (arsine) and \( (\text{CH}_3)_2\text{Te} \) (dimethyl telluride); and the discovery of two new As–sulfur metabolites.

These data indicate the need for more studies with human gut microorganisms, which can confirm the presystemic metabolism as observed with animal gut microbiota. Therefore, in the present study we investigated the metabolic potency of human gut microorganisms toward \( \text{AsH}_3 \) and As from contaminated urban soils, assessing the importance of presystemic As biotransformation upon an oral exposure scenario and the actual speciation of As that enters the bloodstream upon gastrointestinal digestion.

**Materials and Methods**

**Chemicals and media.** We used degassed, ultrapure 18 mΩ water (DDI; Millipore, Bedford, MA, USA) to prepare the chromatographic mobile phase and the standard stock solutions. American Chemical Society–grade ammonium nitrate and ammonium dihydrogen phosphate (Fisher Scientific, Pittsburgh, PA, USA) and technical-grade EDTA, tetrasodium salt dehydrate (Fisher Scientific, Fair Lawn, NJ, USA) were used in the chromatographic mobile phase. We obtained stock solutions of \( \text{As}^{(III)} \) and \( \text{As}^{(V)} \) from Spex Industries (Metuchen, NJ, USA) and certified stock solutions of MMA\( ^V \) and DMA\( ^V \) from Chem Service (West Chester, PA). W.R. Cullen (Department of Chemistry, University of British Columbia, Vancouver, BC, Canada) provided tetramethyl-cyclo-tetraarsaoxane \( [\text{cyclo-(CH}_3\text{AsO}_3]_4 \) crystals that were synthesized and characterized as described elsewhere (Cullen et al. 1989); these crystals were stored at -21°C and were hydrolyzed by degassing, deionized water at the time of analysis to obtain a stock solution of a \( \text{MMA}^{(III)} \) and \( \text{MMA}^{(V)} \) mixture (Cullen et al. 1989). We purchased sodium arsenite \( (\text{Na}_3\text{HAsO}_4\cdot7\text{H}_2\text{O}) \), methionine, methylcobalamin, and glutathione from Sigma-Aldrich (St. Louis, MO, USA). Arsenate stock solutions were prepared in deionized water at 4,500 mg As/L and 45 mg As/L.

**Soils.** The U.S. Environmental Protection Agency kindly provided four As-contaminated soils that originated from urban areas around former smelting sites. We sieved all soils at 250 μm before in vitro gastrointestinal incubation; this sieving reflects the size of particles that most likely sticks to the hands of exposed humans (Kelly et al. 2002). Soil specifications are reported in Table 1.

**Production and characterization of colon microbiota for SHIME.** The in vitro colon microbial community used in this study was cultured and maintained in a modified SHIME, which consisted of four compartments simulating the stomach, small intestine, and both proximal and distal colon. A detailed description of the SHIME, the carbohydrate-based medium, and the in vitro colon microbiota has been described previously (Van de Wiele et al. 2004). Briefly, fecal microbiota previously obtained from a 29-year-old male volunteer (who had no history of antibiotic treatment in the 6 months before the study) were inoculated in the different colon compartments. The SHIME reactor was fed carbohydrate-based medium three times per day to provide digested nutrition for the colon microbiota. After 3 weeks of adaptation, a stable microbial community was obtained in the respective colon compartments. We found microbial fermentation activity of the distal colon (short-chain fatty acid production and ammonia production) and community composition to be consistent with that of previous SHIME runs and the in vivo situation (Molly et al. 1994; Van de Wiele et al. 2004) [see Supplemental Material, Table 1 (doi:10.1289/ehp.0901794)].

**Noncontinuous incubation studies.** **Metabolic potency of fecal microbial inoculum.** The first experiment constituted a screening phase to test whether the fecal microbial community from human origin actively metabolized As. The microbial community was isolated from a fecal sample as previously described by Molly et al. (1994). Thirty milliliters of microbial fecal suspension was sampled, placed in 60-mL serum bottles, and incubated with \( \text{NaH}_2\text{AsO}_4\cdot7\text{H}_2\text{O} \) (\( \text{As}^{(V)} \); 90 mg \( \text{As}^{(V)} \)/L) similar to the method of Herbel et al. (2002). Serum bottles were capped with butyl rubber stoppers that are impervious to \( \text{O}_2 \) and subsequently made anaerobic by flushing with \( \text{N}_2 \) gas for 30 min. Samples were then incubated at 37°C on a rotary shaker (150 rpm) for 48 hr. We compared the effect of specific methyl group donors toward microbial As methylation by comparing methionine-amended (5 mmol/L) and methylcobalamin-amended (5 mmol/L) samples with control samples (incubation of the sample in the presence of heat-sterilized fecal microbiota). The effect of glutathione as a reducing agent was evaluated by comparing glutathione-amended samples (10 mmol/L) with control samples. Duplicate incubations were performed on two different days to evaluate the reproducibility. A scheme of the experimental setup is presented in Supplemental Material, Figure 1 (doi:10.1289/ehp.0901794).

**Metabolic potency of colon microbiota toward As from contaminated soils.** The objective of the second experiment was to screen for microbial speciation changes of \( \text{As}^{(V)} \) at more relevant concentrations (i.e., 50–500 μg/L) by mimicking conditions of oral exposure to environmental samples. In addition, four As-contaminated soil samples (one slag soil and three from urban sites) were subjected to a gastrointestinal digestion procedure. To better mimic in vivo conditions, all gastrointestinal stages—gastric, small intestine, and colon—were simulated. We combined the in vitro gastrointestinal method (IVG) from Ohio State University with the SHIME to subsequently simulate stomach and small intestine (IVG) and colon (SHIME) conditions, respectively. The

### Table 1. Characteristics and elemental composition of the four As-contaminated soils.

| Characteristic | Soil 1 | Soil 2 | Soil 3 | Soil 4 (sign) |
|----------------|--------|--------|--------|--------------|
| Organic carbon (%) | 5.7 | 4.0 | 3.1 | 2.2 |
| pH4+ | 6.1 | 6.3 | 5.0 | 7.2 |
| Electric conductivity (dS/m) | 0.3 | 0.5 | 0.9 | 0.5 |
| Fe (mg/kg) | 14,800 | 15,250 | 12,100 | 202,000 |
| Mn (mg/kg) | 429 | 525 | 207 | 1,640 |
| Reactive Fe2+ | 3,489 | 3,592 | 1,634 | 18,759 |
| Percent bioaccessibility with IVG | 58.5 | 62.4 | 47.7 | 1.0 |
| Toxic trace element content (mg/kg) | | | | |
| As | 990 | 829 | 379 | 837 |
| Cadmium | 9.7 | 5.5 | 1.5 | 28.9 |
| Chromium | 32.0 | 31.4 | 28.7 | 187 |
| Copper | 51.9 | 60.1 | 22.2 | 1,520 |
| Molybdenum | 2.1 | 2.4 | 1.5 | 73.9 |
| Nickel | 12.5 | 10.9 | 9.3 | 10.4 |
| Lead | 885 | 602 | 172 | 8,702 |
| Selenium | 330 | 430 | 127 | 294 |
| Zinc | 562 | 803 | 151 | 12,500 |

*Soil pH was determined in a 1:10 (wt/vol) aqueous soil slurry. Iron dissolved by acid ammonium oxalate extraction. Data from Whitacre (2009).
IVG method was previously validated against in vivo data for As bioaccessibility (Rodriguez and Basta 1999), whereas the SHIME has been validated against in vivo data for microbial community composition and metabolic activity toward drugs and phytoestrogens (Molly et al. 1994; Posemiers et al. 2006).

Soils were incubated in the gastric and intestine solution (30 mL) of the IVG protocol at a liquid-to-soil (L/S) ratio of 150 (Rodriguez and Basta 1999). These intestinal digests from the IVG protocol were subjected to colon conditions by adding 30 mL of the colon suspension sampled from the distal colon compartment of the SHIME reactor, resulting in an L/S ratio of 300 for the soil digests. The vessels containing the colon digest were capped with butyl rubber stoppers and subsequently flushed with N₂ for 30 min to obtain anaerobic conditions and incubated on a shaker at 150 rpm at 35°C for 18 hr. See Supplemental Material, Figure 1 (doi:10.1289/ehp.0901794) for a schematic of the experimental setup.

**Sample treatment.** To preserve the speciation of As in the colon digests, all samples were flash frozen with liquid nitrogen upon incubation and subsequently stored at −80°C. Before analysis with high-performance liquid chromatography (HPLC) coupled with inductively coupled plasma (ICP) mass spectrometry (MS), samples were thawed and diluted appropriately with 20 mmol/L (NH₄)₂CO₃ at pH 9.0 to minimize sulfur–oxygen exchange while awaiting analysis (Gonklin et al. 2008). Upon complete thawing, the sample was vortexed and centrifuged for 10 min at 10,400 relative centrifugal force with an Eppendorf 5810R centrifuge (Brinkmann Instruments, Westburg, NY, USA) to separate soluble As species from soil-bound As. The supernatant was filtered through a Millipore LCR 0.45 µm filter (Millipore) with a Luer-Lok 10-mL syringe (BD, Franklin Lakes, NJ, USA). Finally, filtrates were diluted with the mobile phase and injected into the HPLC. The sum of the As species in the filtrate observed chromatographically was considered the bioaccessible fraction. We measured total As concentration in the digest filtrates using ICP optical emission spectrometry (ICP-OES). This allowed us to calculate chromatographic recovery, which quantifies the extent to which the sum of the chromatographic As species comprises the total amount of As in the digest filtrates.

**As speciation analysis by HPLC/ICP-MS.** Sample supernatants were analyzed with HPLC (Agilent 1100) and ICP-MS (Agilent 7500ce; Agilent, Palo Alto, CA, USA) for As specific detection at m/z 75. Separation of As oxides was performed on a PRP-X100 HPLC column (250 mm × 4.1 mm, 5 µm). The mobile phase was a solution of NH₄NO₃ (10 mmol/L), NH₄H₂PO₄ (10 mmol/L), and EDTA (500 mg/L) at pH 4.57 in distilled water (separation 1). The flow rate was 1.0 mL/min, and the sample injection volume was 100 µL. The retention times of the separated compounds were 3.6 min for As(III), 4.2 min for DMA, 5.5 min for MMA, 7.1 min for MMA, and 8.9 min for As(V), similar to those previously reported by Yathavalkia et al. (2008). We used this separation for quantification of the As species of interest. Arsenic sulfides were identified by retention-time matching between samples and fortified samples. Using chromatographic separation 1, monothioarsonic acid eluted at 15 min, whereas MMMTA eluted at 18.6 min. See the Supplemental Material (doi:10.1289/ehp.0901794) for details on synthesis, chromatographic confirmation of these As sulfides, and sample analysis.

A second chromatography [separation 2; see Supplemental Material (doi:10.1289/ehp.0901794)] was used for ICP-MS and electrospray ionization (ESI)-MS detection, because the mobile phase of separation 1 was not compatible with ESI-MS detection.

**Results.** In the first experiment, we assessed the metabolic potency of the human fecal microbial inoculum toward high levels of iAs³V (90 mg/L). iAs⁴V was efficiently (> 94%) reduced to iAs²⁴V after the 48-hr incubation with both active and sterilized fecal microbiota (Table 2), probably because of the highly reducing conditions (redox potential was −180 mV). Incubation with sterilized fecal microbiota did not lead to thiolytated or methylated arsenicals. In contrast, incubation of iAs³V with active fecal microbiota resulted in the production of monooxoasmonic acid (mTA; mean ± SD in nanomol (2.2 ± 3.1 mL) and methionine-amended (0.8 ± 1.1 mL) samples. Interestingly, we observed methylation only in the presence of methylcobalamin. Addition of the methylcobalamin displayed a significant methylation of iAs³V (18%), with MMA³V (13.0 ± 1.4 mg/L) being more dominant than MMA²IV (2.6 ± 1.4 mg/L). The addition of both methylcobalamin and glutathione as a reducing agent increased the methylation to 28%, with MMA³IV (10.5 ± 5.4 mg/L) becoming equally as important as MMA³V (11.3 ± 5.6 mg/L).

These preliminary data convinced us that the selected microbial community had the potency to actively metabolize iAs³V. We therefore inoculated the SHIME reactor with this fecal microbial inoculum; after 3 weeks of adaptation, a stable microbial community was obtained in the proximal and distal colon compartments. We regularly sampled the distal colon compartment to perform colonic incubations on iAs³V and As-contaminated soil samples that had already gone through a gastric and intestinal digestion. Characterization of the colon digests consisted of determining As bioaccessibility and As speciation. The bioaccessibility determination was based on the sum of all chromatographically detected (HPLC/ICP-MS) As species in the filtrates (0.45 µm) of the colon digests; therefore, the chromatographic recovery was calculated first. The sum of the concentrations of chromatographically detected As species in the colon digests were analyzed by HPLC/ICP-MS.

**Table 2.** Influence of cofactors toward microbial metabolism during in vitro fecal incubation of iAs³V at 90 mg/L.

| Microbiota | As³V | As⁴V | MMA³V | MMA⁴V | mTA | Recovery (%) |
|------------|------|------|-------|-------|-----|--------------|
| No cofactor | 1.7 ± 2.3 | 97.8 ± 2.5 | ND | ND | 2.2 ± 3.1 | 113 |
| Me-B12 | 2.6 | 65.3 | 13.0 ± 1.4 | 2.6 ± 1.4 | ND | 93 |
| MeH | 1.2 ± 2.3 | 102.4 ± 3.1 | ND | ND | 0.8 ± 1.1 | 119 |
| GSH | ND | 93.2 ± 18.8 | ND | ND | ND | 104 |
| Me-B12/Meth | 2.0 ± 1.2 | 536 ± 9.7 | 11.3 ± 5.6 | 10.5 ± 5.4 | ND | 86 |
| Sterilized microbiota | 5.6 | 97.6 | ND | ND | ND | 104 |
| Me-B12 | 4.6 | 72.7 | ND | ND | ND | 86 |
| MeH | 4.6 | 86.8 | ND | ND | ND | 102 |
| GSH | ND | 84.6 | ND | ND | ND | 94 |
| Me-B12/Meth | 3.5 | 83.7 | ND | ND | ND | 97 |

Abbreviations: GSH, glutathione; Me-B12, methylcobalamin; Meth, methionine; ND, not detected. Values are mean ± SD (mg/L) from duplicate incubation experiments.

*Incubation tests with sterilized microbiota were performed once, so no SD is available.

**Table 3.** Percentage bioaccessibility of As and biomass-specific production rate of methylated arsenicals by colon microorganisms after in vitro colon digestion of iAs³V (225 µg/L) and As-contaminated soils.

| Sample | Percent bioaccessibility² (µg/hr/g biomass)³ | Methylation rate⁴ (µg/hr/g biomass)³ |
|--------|---------------------------------------------|-----------------------------------|
| Na₂H₂AsO₄·3H₂O | 76 ± 14.3 | 10.0 ± 4.0 |
| Soil 1 | 24 ± 4.3 | 10.0 ± 1.8 |
| Soil 2 | 44 ± 3.9 | 4.2 ± 1.6 |
| Soil 3 | 36 ± 1.5 | 28.3 ± 3.4 |
| Soil 4 | 0.3 ± 0.1 | ND |

ND, not detected. Values are mean ± SD of three experiments.

*Calculated by dividing the sum of detected As species (iAs³V, iAs⁴V, mTA, MMA³V, MMA⁴V, and MMMTA) in the colon digest filtrate by the total amount of As that was incubated under colon conditions. *Calculated by dividing the sum of methylated arsenicals (MMA³V, MMA⁴V, and MMMTA) in the colon digest filtrate by the initial biomass concentration and the incubation time.
filtrates was divided by the total As concentration in the colon filtrates, as measured by ICP-OES. The chromatographic recoveries for all colon digests, except for that of soil 4, were satisfactorily high: 93 ± 7% (mean ± SD) on average [the recovery of the soil 4 digest excluded; see Supplemental Material, Table 2 (doi:10.1289/ehp.0901794)]. Hence, most As species present in these digest supernatants could be detected with the HPLC/ICP-MS protocol. Bioaccessibility calculations for these digests displayed the highest value (75.5%) for the iAsV- incubated colon digest, whereas colon incubation of the contaminated soils resulted in As bioaccessibility values of 24% (soil 1), 44% (soil 2), and 36% (soil 3) (Table 3). In sharp contrast, As bioaccessibility in the colon digest of soil 4 was only 0.3%. Even when taking into account the low chromatographic recovery of 15%, we obtained a low As bioaccessibility of 2.4%, which is still an order of magnitude lower than the bioaccessibility values for the other soil digests. Overall, colon bioaccessibility values (Table 3) for the four soils were consistently lower than the corresponding intestinal bioaccessibility values (Table 1) obtained with the IVG method.

The most important part of this study consisted of the As speciation analysis of the colon digests after the gastrointestinal incubation of iAsV and the four contaminated soils. The original analytical protocol was optimized to detect the presence of iAsIII, iAsV, MMAV, and MMAIII. We detected an additional As species, MMMTAV, in many of the colon digests. We initially identified MMMTAV using a combination of retention-time matching and by fortifying the sample with the suspected standard using separation 1 with ICP-MS detection, but we used a second chromatography (separation 2) for ICP-MS and ESI-MS detection. Figure 1 shows HPLC/ICP-MS mass chromatograms of m/z 75 (\textsuperscript{75}As) and HPLC/ESI-MS mass chromatograms of m/z 155 ([M+H]\textsuperscript{+}) for an MMMTAV standard and a SHIME extract using separation 2. The retention times of the MMMTAV in the standard and MMMTAV in the sample were slightly offset because the matrix of the soil extract caused the decreased retention of MMMTAV on the C\textsubscript{18} column. Tandem MS (MS/MS) of m/z 155 yielded a product ion of m/z 137 (loss of H\textsubscript{2}O) and, to a lesser extent, a product ion of m/z 121 (due to CH\textsubscript{3}AsO\textsubscript{3}) and m/z 140 (loss of CH\textsubscript{3}). The molecular mass of 155 and corresponding fragments were consistent with other reports for MMMTAV (Yathavakilla et al. 2008).

We detected significant As methylation upon colon incubation of 225 µg iAsV/L (Figure 2). The sum of the concentrations of MMAV (31.0 µg/L), MMAIII (4.5 µg/L), and MMMTAV (43.7 µg/L) exceeded that of iAsV (39.0 µg/L) and iAsIII (34.8 µg/L). In contrast, iAs species were predominantly present in colon digests of soils 1, 2, and 3, whereas they were the only As species in the colon digest of slag soil 4 (Figure 2). The colon digest of soil 1 displayed a methylation percentage of 4.7% with MMAV (17 µg/L) and MMMTAV...
importance. Although the absorption kinetics of MMMTA\textsuperscript{V} and other thiolated arsenicals across the epithelium are unknown, there is evidence that some methylated thioarsenicals elicit a higher toxicity than iAs\textsuperscript{V} because of their more efficient absorption by mammalian cells (Naranmandura et al. 2007a).

Summarizing the in vitro As speciation changes by human gut microorganisms, we calculated the specific production rates of methylated arsenicals by taking into account the initial microbial biomass and As concentrations. We obtained a methylation rate of 10 µg methylarsenicals/g biomass/hr for the colon digest of iAs\textsuperscript{V} (Table 3). Although no methylarsenicals were detected in colon digests of the slag soil 4, the presence of the other soil matrices did not necessarily lower the above-mentioned methylation rate. We obtained methylation rates of 4, 29, and 10 µg/g/hr for colon digests of soils 1, 2, and 3, respectively (Table 3).

**Discussion**

The present study demonstrates that human colon microorganisms have the potency to actively metabolize As into methylated arsenicals and thioarsenicals, which indicates that presystemic As metabolism may not be neglected when assessing risks from oral As exposure. We observed this upon colon incubation of both iAs and As-contaminated soils. These findings parallel those from studies with animal gut microbiota (Hall et al. 1997; Rowland and Davies 1981) and suggest the existence of a presystemic As metabolism in the human body. The most important result was the detection of significant levels of MMMTA\textsuperscript{V} in colon digests of both iAs\textsuperscript{V} (25% of bioaccessible As) and of As-contaminated soils (up to 20% of bioaccessible As). To our knowledge, this is the first time that MMMTA\textsuperscript{V} production from iAs\textsuperscript{V} by human colon microbiota has been described. MMMTA\textsuperscript{V} production from this source resembles the methylation and thiolation of DMA\textsuperscript{V} into trimethylarsine sulfide by mouse cecal microbiota (Kubachka et al. 2009a) and the production of methylated thioarsenicals from DMA\textsuperscript{V} by rat intestinal microbiota (Kuroda et al. 2004; Yoshida et al. 2001). Yet, mammalian cells also have the ability to form methylated thioarsenicals. Kuroda et al. (2004) described rapid detection (5 min) of DMDTA\textsuperscript{V} and dimethylidithioarsinic acid (DMDTA\textsuperscript{V}) after injection of of rats with DMA\textsuperscript{III}, and Naranmandura and Suzuki (2008) reported that DMA\textsuperscript{III} was converted to DMDTA\textsuperscript{V} by human red blood cells.

The finding of presystemic MMMTA\textsuperscript{V} formation by human gut microorganisms raises questions about its toxicological importance. Although the absorption kinetics of MMMTA\textsuperscript{V} and other thiolated arsenicals across the epithelium are unknown, there is evidence that some methylated thioarsenicals elicit a higher toxicity than iAs\textsuperscript{V} because of their more efficient absorption by mammalian cells (Naranmandura et al. 2007a).

Preliminary cytotoxicity (Naranmandura et al. 2007a; Yoshida et al. 2003) and genotoxicity (Kuroda et al. 2004) data for DMDTA\textsuperscript{V} show levels of toxicity similar to those of trivalent As species. Our observations in the present study emphasize the need to investigate the behavior of MMMTA\textsuperscript{V} in the gut lumen and the absorption rate across the intestinal epithelium. In addition, the mechanism behind the microbial production pathway needs to be elucidated. Interestingly, MMMTA\textsuperscript{V} levels in the colon digests correlated with those of MMA\textsuperscript{V} (R² = 0.76), whereas the correlation with levels of MMA\textsuperscript{III} was much lower (R² = 0.42). This seems to indicate that MMMTA\textsuperscript{V} in the colon digests arises from the thiolation of MMA\textsuperscript{V}, which would correspond with earlier observations describing the interconversion between oxide and sulfide forms of MMA\textsuperscript{V}, DMA\textsuperscript{V}, and TMAO (Conklin et al. 2008). The sulfide source may originate from microbial sulfate reduction to hydrogen sulfide, which is a common process in the colon environment (Deplancke et al. 2000), and can trigger the formation of thioarsensugars upon the incubation of arsenosugars with mouse cecal contents (Conklin et al. 2006). The role of sulfate-reducing microorganisms in the presystemic production pathway of MMMTA\textsuperscript{V} must therefore be studied further.

The significant formation of MMA\textsuperscript{V} and MMA\textsuperscript{III} after incubation of iAs\textsuperscript{V} with colon microorganisms was not unexpected. Arsenic methylation by rodent gut microbes (Hall et al. 1997; Rowland and Davies 1981) and human gut microbes (Díaz-Bone and Van de Wiele 2009; Meyer et al. 2008) has been described previously. Taking into account the initial biomass concentration, we observed specific methylation rates of 10 µg methylarsenicals/hr/g biomass. This roughly corresponds to 130 pmol/hr/mg biomass, which is > 16 pmol/hr/mg obtained with rat cecal microbiota (Hall et al. 1997). Interestingly, the presence of a soil matrix did not necessarily result in lower As methylation rates, yet soil-dependent parameters may have affected the methylation rate. First, comparison of the mineralogy from soils 1, 2, and 3 with that of slag (soil 4) showed an important difference in reactive iron oxide content (Table 1), which is highly efficient in sorbing As (Beak et al. 2006). The reactive iron oxide content in slag soil 4 was particularly high (18,759 µg/kg; Table 1), presumably leading to much lower As availability to colon microorganisms (0.3% bioaccessibility) and thus also limiting methylation. This observation may confirm earlier observations of slag soil mineralogy significantly decreasing As bioavailability (Davis et al. 1996). A second element in the soil-dependent As methylation may be the difference in toxic elements. Compared with the first three soils, slag (soil 4) contained high amounts of cadmium, chromium, copper, molybdenum, lead, and zinc (Table 1), which may be toxic to intestinal microorganisms. Our finding of a 70% lower fermentation activity in soil 4 colon digests versus colon digests of the other soils (data not shown) may support the assumption of slag-soil–induced toxicity. The actual relationship between gut microbial As metabolism and soil characteristics therefore needs further study.

A final aspect of our study concerns the metabolic potency of fecal microbes toward high levels of iAs\textsuperscript{V} (90 mg iAs\textsuperscript{V}/L) and the influence of cofactors. Nonamended colon digests of iAs\textsuperscript{V} resulted in the efficient reduction to iAs\textsuperscript{III} and the production of mTA. Similar to the finding of MMMTA\textsuperscript{V}, the formation of mTA may result from an oxygen-for-sulfur exchange in iAs\textsuperscript{V} because of the availability of sulfide, originating from the above-mentioned microbial sulfate reduction. The absence of mTA in glutathione-amended samples may be explained by the complete reduction of iAs\textsuperscript{V} into iAs\textsuperscript{III} by glutathione as reducing agent. We also evaluated the effect of methyl group donors. In contrast to methionine, methylcobalamin may be an effective methyl group donor, resulting in the efficient methylation (19%) of iAs\textsuperscript{V} into MMA\textsuperscript{V} and MMA\textsuperscript{III} (Table 2). The methylation efficiency increased to 25% upon cosupplementation of methylcobalamin and glutathione. We attributed this to the increased reduction of MMA\textsuperscript{V} into MMA\textsuperscript{III} by glutathione as reducing agent. In contrast to the colon digests with low levels of iAs\textsuperscript{V} (225 µg/L), no MMMTA\textsuperscript{V} was detected in the fecal digests. A probable explanation is the difference in experimental setup, the difference in microbial community composition and activity, or a difference in sulfide availability. These observations confirm a previous report that addition of cofactors may increase As methylation by enteric microorganisms, yet it is not a prerequisite for the methylation of low levels of As (micrograms per liter range) (Hall et al. 1997).

The present study provides evidence for the existence of significant presystemic As metabolism by human gut microorganisms, but the relevance for the total risk of oral As exposure is not yet clear. So far, the in vitro approach for assessing the risks from oral contaminant exposure mainly involved the use of models that focus on gastric and intestinal processes. Methylation of As by intestinal microorganisms was thought
to contribute little to the overall methylation in vivo (Vahter and Gustafsson 1980) because AsV and AsIII are rapidly absorbed in the small intestine (Vahter 1983), especially when As is ingested in a soluble matrix (e.g., drinking water). However, soil-bound and/or dietary-bound As may follow a different digestion scenario in the gut, and a large fraction may end up in the colon lumen, where it is subjected to the resident microbial community. The finding of MMMAV and the highly toxic MMAIII as metabolites from human colon microorganisms indicates that presystemic methylation will not lead to detoxification. In addition, in vitro studies with Caco-2 human epithelial colo rectal adenocarcinoma cells suggest that the absorption of methylated arsenicals (DMAV, 10.0%; TMAO, 10.9%) is more efficient than that of iAsIII (5.8%) and iAsV (1.6%) (Laparra et al. 2005, 2007). Intestinal absorption of methylated thioarsenicals should be examined in future research.

Regarding the variability between individuals regarding presystemic As metabolism, we investigated the gut microbiota from only one human. Interindividual variability in gut microbial composition is very high; thus, we expect gut microbiota from different individuals to display distinct As metabolic profiles. Such interindividual variation in metabolism by human gut microbiota was previously reported for ingested phytoestrogens (Bolca et al. 2007) and, interestingly, also for the metalloid bismuth (Michalke et al. 2008). Therefore, variability in gut microbial As metabolism should be given the same attention as the generic variations that may govern interindividual differences in As response (Hernandez and Marcos 2008).

Conclusion

The present study shows that presystemic metabolism of soil-derived As may be relevant in the human body when significant amounts of As become available to colon microorganisms. The absorption kinetics of methylated arsenicals and thioarsenicals across the gut epithelium and their toxicity need further elucidation. We propose that the metabolic activity of human colon microorganisms be incorporated in development of new toxicokinetic models that assess risks from oral As exposure. Mikov (1994) nicely summarized the importance of gut microbiota, stating that gut microbial metabolism must be considered an integral part of drug/xenobiotic metabolism and toxicity studies. In this context, knowledge about gut microbial metabolism must also be translated to metalloid biotransformation.

**References**

Beak DG, Basta NT, Scheckel KG, Traina SJ. 2006. Bioavailability of arsenic(V) bound to fenarylhydridine using a simulated gastro intestinal system. Environ Sci Technol 40:1364–1370.

Bolca S, Possemiers S, Herregat I, Huybregts I, Heyerick A, De Vriese S, and Van de Wiele T. 2003. Microbial and dietary factors are associated with the equal producer phenotype in healthy postmenopausal women. J Nutr 137:2242–2246.

Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:889–902.

Chen H, Yoshida K, Waniabuchi H, Fukushima S, Inoue Y, Endo G. 1996. Methylation and demethylation of dimethylarsinic acid in rats following chronic oral exposure. Appl Organomet Chem 10(9):741–745.

Conklin SD, Ackerman AH, Fricke MW, Creed PA, Creed JT, Kohan MC, et al. 2006. In vitro biotransformation of an arsenic species: the metabolic activity of human colon microorganisms is very high; thus, we expect gut microbiota from different individuals to display distinct As metabolic profiles. Such interindividual variation in metabolism by human gut microbiota was previously reported for ingested phytoestrogens (Bolca et al. 2007) and, interestingly, also for the metalloid bismuth (Michalke et al. 2008). Therefore, variability in gut microbial As metabolism should be given the same attention as the generic variations that may govern interindividual differences in As response (Hernandez and Marcos 2008).

**Conclusion**

The present study shows that presystemic metabolism of soil-derived As may be relevant in the human body when significant amounts of As become available to colon microorganisms. The absorption kinetics of methylated arsenicals and thioarsenicals across the gut epithelium and their toxicity need further elucidation. We propose that the metabolic activity of human colon microorganisms be incorporated in development of new toxicokinetic models that assess risks from oral As exposure. Mikov (1994) nicely summarized the importance of gut microbiota, stating that gut microbial metabolism must be considered an integral part of drug/xenobiotic metabolism and toxicity studies. In this context, knowledge about gut microbial metabolism must also be translated to metalloid biotransformation.

**References**

Beak DG, Basta NT, Scheckel KG, Traina SJ. 2006. Bioavailability of arsenic(V) bound to fenarylhydridine using a simulated gastro intestinal system. Environ Sci Technol 40:1364–1370.

Bolca S, Possemiers S, Herregat I, Huybregts I, Heyerick A, De Vriese S, and Van de Wiele T. 2003. Microbial and dietary factors are associated with the equal producer phenotype in healthy postmenopausal women. J Nutr 137:2242–2246.

Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:889–902.

Chen H, Yoshida K, Waniabuchi H, Fukushima S, Inoue Y, Endo G. 1996. Methylation and demethylation of dimethylarsinic acid in rats following chronic oral exposure. Appl Organomet Chem 10(9):741–745.

Conklin SD, Ackerman AH, Fricke MW, Creed PA, Creed JT, Kohan MC, et al. 2006. In vitro biotransformation of an arsenic species: the metabolic activity of human colon microorganisms is very high; thus, we expect gut microbiota from different individuals to display distinct As metabolic profiles. Such interindividual variation in metabolism by human gut microbiota was previously reported for ingested phytoestrogens (Bolca et al. 2007) and, interestingly, also for the metalloid bismuth (Michalke et al. 2008). Therefore, variability in gut microbial As metabolism should be given the same attention as the generic variations that may govern interindividual differences in As response (Hernandez and Marcos 2008).

**Conclusion**

The present study shows that presystemic metabolism of soil-derived As may be relevant in the human body when significant amounts of As become available to colon microorganisms. The absorption kinetics of methylated arsenicals and thioarsenicals across the gut epithelium and their toxicity need further elucidation. We propose that the metabolic activity of human colon microorganisms be incorporated in development of new toxicokinetic models that assess risks from oral As exposure. Mikov (1994) nicely summarized the importance of gut microbiota, stating that gut microbial metabolism must be considered an integral part of drug/xenobiotic metabolism and toxicity studies. In this context, knowledge about gut microbial metabolism must also be translated to metalloid biotransformation.

**References**

Beak DG, Basta NT, Scheckel KG, Traina SJ. 2006. Bioavailability of arsenic(V) bound to fenarylhydridine using a simulated gastro intestinal system. Environ Sci Technol 40:1364–1370.

Bolca S, Possemiers S, Herregat I, Huybregts I, Heyerick A, De Vriese S, and Van de Wiele T. 2003. Microbial and dietary factors are associated with the equal producer phenotype in healthy postmenopausal women. J Nutr 137:2242–2246.

Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:889–902.

Chen H, Yoshida K, Waniabuchi H, Fukushima S, Inoue Y, Endo G. 1996. Methylation and demethylation of dimethylarsinic acid in rats following chronic oral exposure. Appl Organomet Chem 10(9):741–745.

Conklin SD, Ackerman AH, Fricke MW, Creed PA, Creed JT, Kohan MC, et al. 2006. In vitro biotransformation of an arsenic species: the metabolic activity of human colon microorganisms is very high; thus, we expect gut microbiota from different individuals to display distinct As metabolic profiles. Such interindividual variation in metabolism by human gut microbiota was previously reported for ingested phytoestrogens (Bolca et al. 2007) and, interestingly, also for the metalloid bismuth (Michalke et al. 2008). Therefore, variability in gut microbial As metabolism should be given the same attention as the generic variations that may govern interindividual differences in As response (Hernandez and Marcos 2008).

**Conclusion**

The present study shows that presystemic metabolism of soil-derived As may be relevant in the human body when significant amounts of As become available to colon microorganisms. The absorption kinetics of methylated arsenicals and thioarsenicals across the gut epithelium and their toxicity need further elucidation. We propose that the metabolic activity of human colon microorganisms be incorporated in development of new toxicokinetic models that assess risks from oral As exposure. Mikov (1994) nicely summarized the importance of gut microbiota, stating that gut microbial metabolism must be considered an integral part of drug/xenobiotic metabolism and toxicity studies. In this context, knowledge about gut microbial metabolism must also be translated to metalloid biotransformation.